secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001493152-25-006471
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma Q3 fiscal 2025 revenue $14.4M (-8% YoY); operating profit $1.1M (-69%)
--------------------------------------------------------------------------------

- Consolidated revenue $14.4M for quarter ended Dec 31, 2024, down 8% from $15.6M in prior-year period.
- Operating profit fell 69% to $1.1M from $3.5M; company cites year-end holiday shipment delays.
- Shipments delayed into first week of January 2025 due to timing differences at December holiday period.
- No EPS, net income, or updated guidance provided in the release; conference call scheduled Feb 14.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315225006471/0001493152-25-006471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315225006471/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-006471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer